Early benefit with empagliflozin in heart failure with preserved ejection fraction: insights from the EMPEROR-Preserved trial

Eur J Heart Fail. 2022 Feb;24(2):245-248. doi: 10.1002/ejhf.2420. Epub 2022 Jan 18.
No abstract available

MeSH terms

  • Benzhydryl Compounds / therapeutic use
  • Glucosides / therapeutic use
  • Heart Failure* / drug therapy
  • Humans
  • Stroke Volume

Substances

  • Benzhydryl Compounds
  • Glucosides
  • empagliflozin